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Abstract
Background: Regional lymph node metastasis is an important prognostic factor in head and neck
squamous cell carcinoma (HNSCC) and plays a decisive role in the choice of treatment. Here, we
present an independent gene expression validation study of metastasized versus non-metastasized
HNSCC.
Methods: We used a dataset recently published by Roepman et al. as reference dataset and an
independent gene expression dataset of 11 metastasized and 11 non-metastasized HNSCC tumors
as validation dataset. Reference and validation studies were performed on different microarray
platforms with different probe sets and probe content. In addition to a supervised gene-based
analysis, a supervised pathway-based analysis was performed, evaluating differences in gene
expression for predefined tumorigenesis- and metastasis related gene sets.
Results:  The gene-based analysis showed 26 significant differentially expressed genes in the
reference dataset, 21 of which were present on the microarray platform used in the validation
study. 7 of these genes appeared to be significantly expressed in the validation dataset, but failed to
pass the correction for multiple testing. The pathway-based analysis revealed 23 significant
differentially expressed gene sets, 7 of which were statistically validated. These gene sets are
involved in extracellular matrix remodeling (MMPs, MMP regulating pathways and the uPA system),
hypoxia and angiogenesis (HIF1α regulated angiogenic factors and HIF1α regulated invasion).
Conclusion:  Pathways that are differentially expressed between metastasized and non-
metastasized HNSCC are involved in the processes of extracellular matrix remodeling, hypoxia and
angiogenesis. A supervised pathway-based analysis enhances the understanding of the biological
context of the results, the comparability of results across different microarray studies, and reduces
multiple testing problems by focusing on a limited number of pathways of interest instead of
analyzing the large number of probes available on the microarray.
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Background
Head and neck squamous cell carcinoma is a relatively
common malignancy, associated with severe disease- and
treatment-related morbidity. One of the most predictive
factors of poor clinical outcome is the presence of regional
lymph node metastasis, and nodal status of the neck plays
a decisive role in the choice of treatment [1,2]. The com-
plex process of metastasis in HNSCC is still incompletely
understood at a molecular level; however, multiple
marker studies have been performed in order to identify
markers that predict the presence of metastasis. Recently,
high-throughput gene expression studies have been able
to identify a metastatic gene expression signature in pri-
mary HNSCC tumors, and Roepman et al. were able to
predict the presence of lymph node metastasis based on
gene expression of the primary tumor [3]. Analyses in this
study were performed in a 'data-driven' way, by means of
computational statistics without prior implementation of
existing knowledge about functionally related genes and
pathways. This technique is very useful in the search for
new biomarkers, new subgroups, and differences in their
gene expression profiles. Although the authors were able
to identify a number of genes that are known to be
involved in metastatic disease within this gene set, the
interpretation of statistical differences in a meaningful
molecular biological context is not self-evident. It has
been demonstrated that classification gene sets are pro-
foundly influenced by the microarray methodology, such
as the microarray technique, microarray platform, and
preprocessing methods [4-8]. Furthermore, it has been
shown that classifying gene sets are highly dependent on
the chosen analysis strategy [9,10]. This is illustrated by
the fact that the authors were able to generate several dif-
ferent classifying gene sets that were all able to predict
nodal metastasis with reasonable accuracy [10]. The
dependence of classifying gene sets on statistical methods,
as well as technical methods such as choice of microarray
platform, hampers comparability of results from different
microarray studies and raises questions about the biolog-
ical relevance of the classifying genes. It is therefore neces-
sary that differences in gene expression are validated in an
independent dataset. Here, we present an independent
gene expression validation study of metastasized versus
non-metastasized HNSCC. Differences in gene expression
between metastasized and non-metastasized HNSCC
were determined in the publicly available dataset gener-
ated by Roepman et al., and subsequently validated in an
independent gene expression dataset of 11 metastasized
and 11 non-metastasized HNSCC tumors of three ana-
tomical localizations (the oral cavity, the oropharynx and
the larynx). In addition to the validation of individual dif-
ferentially expressed genes, we performed a supervised,
pathway-based analysis. Gene expression was evaluated
within predefined subgroups of genes with a known bio-
logical context, i.e. genes within a metastasis related path-
way. First, pathways and functional gene clusters that are
involved in the process of metastasis in carcinoma were
defined using pathways described in literature and the
publicly available Kyoto Encyclopedia of Genes and
Genomes (KEGG) and Biocarta pathway databases, with a
focus on pathways involved in survival, proliferation,
apoptosis, cell adhesion, extra cellular matrix signaling
and remodeling, hypoxia and angiogenesis [11-13]. Using
this supervised analysis strategy, we found considerable
concordance between the datasets for pathways involved
in survival, proliferation, apoptosis, cell adhesion, extra
cellular matrix signaling and remodeling, hypoxia and
angiogenesis. Gene sets that were validated by the inde-
pendent validation dataset were matrix metalloprotein-
ases (MMPs) and pathways involved in MMP regulation,
the uPA system and pathways involved in uPA regulation,
and HIF1α regulated invasion and angiogenesis. This
approach to microarray analysis generates an outcome
with readily interpretable biological meaning. Further-
more, by concentrating on groups of genes with a known
biological relation rather than individual genes, compara-
bility of microarray studies performed on different micro-
array platforms is improved [14].
Methods
Reference dataset
The publicly available HNSCC gene expression dataset
published by Roepman and co-workers was used as the
reference dataset [3,15]. All 104 samples (49 non-metas-
tasized and 55 metastasized primary head and neck carci-
noma's) analyzed in this study were included the
reference dataset (Table 1). For sample selection, cRNA
preparation, microarray hybridization and normalization
methods in this study see elsewhere [3].
Validation dataset
Sample selection
An independent validation dataset was constructed using
fresh frozen tumor tissue of 24 patients with an HNSCC
originating from the oral cavity, the oropharynx, or the
larynx. Primary tumors were removed between 1990 and
2000. Specimens were selected from the frozen tissue
bank of the Leiden University Medical Centre (LUMC),
the Netherlands. Neck dissection specimens of all cases
were available for histological evaluation of lymph nodes.
Based on histology obtained from surgical specimens as
well as clinical and radiological data collected during a
follow-up period of four years or more, the group was
divided into a non-metastasized and a metastasized sub-
group. The non-metastasized group consisted of 12
tumors (4 from the oral cavity, 4 oropharyngeal and 4
laryngeal HNSCC) from patients without indication of
metastasis at the time of surgery, nor during the follow-up
period. The metastasized group also consisted of 12
tumors (4 from the oral cavity, 4 oropharyngeal and 4BMC Cancer 2008, 8:168 http://www.biomedcentral.com/1471-2407/8/168
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laryngeal HNSCC) from patients with lymph node metas-
tasis at the time of surgery or during the follow-up period
(Table 1). In all cases fresh frozen tissue of the primary
tumor containing a tumor percentage of 50% or more,
paraffin material, an unequivocal pathological classifica-
tion of the resection material and clinical data were avail-
able. Patients who had undergone radiotherapy before
surgical excision of the tumor or had a previous malig-
nancy in the same region were excluded. All specimens
were handled according to the ethical guidelines, as
described in the Code for Proper Secondary Use of
Human Tissue in the Netherlands of the Dutch Federation
of Medical Scientific Societies (FEDERA). The data dis-
cussed in this publication have been deposited in NCBIs
Gene Expression Omnibus (GEO), and are accessible
through GEO Series accession number GSE9349 [16].
High-density oligonucleotide arrays
Data from the reference dataset were obtained with the
Human Array-Ready Oligo set, version 2.0 (Qiagen)
printed on Corning UltraGAPS slides, containing over
21,000 genes. These data were compared to the data from
the validation set, obtained with Affymetrix HG-Focus
Target arrays (Affymetrix, Inc., Santa Clara, CA) as micro-
array platform, containing over 190,000 unique oligonu-
cleotides, representing more than 8,500 of the best
characterized human genes.
Total RNA isolation, probe preparation and hybridization to arrays
Total RNA isolation, probe preparation and hybridization
to arrays were performed according to the Affymetrix pro-
tocols. In short, total RNA was extracted from fresh frozen
tumor sections using Trizol (Invitrogen, San Diego, CA).
Total RNA was precipitated with glycogen and isopropa-
nol, washed with ethanol and purified using the RNeasy
Mini Kit (Qiagen, Valencia, CA). Total RNA yield and
purity were measured using spectrophotometric analysis
and in addition RNA quality was checked on a 1% agarose
gel. Double-stranded cDNA synthesis was performed
using the Superscript Choice system (Life Technologies,
Rockville, MD); incorporating the T7 RNA polymerase
promoter in the first round. The resulting ds cDNA was
purified using the QIAquick PCR Purification Kit (Qiagen,
Valencia, CA), and applied as a template for in vitro tran-
scription using the RNA Transcript Labeling Kit (Enzo
Diagnostics, Inc., Farmingdale, NY), incorporating bioti-
nylated ribonucleotides required for the staining proce-
dures after hybridization. The resulting cRNA was purified
as described above and cRNA quantity and quality were
measured using spectrophotometric analysis and the
2100 Bioanalyzer (Agilent, Palo Alto, CA). 15 μg frag-
mented, biotinylated cRNA was hybridized to the Affyme-
trix HG-Focus Target arrays at 45°C for 16 h. After
hybridization the arrays were washed, stained and
scanned, as described in the Affymetrix users' manual.
Statistical analysis
Normalization and expression analysis
In the validation study, acquisition and quantification of
array images was performed using the MAS software pack-
age (Affymetrix). All arrays were normalized with gcrma
normalization and custom probe definitions based on
EntrezGene identifiers using the R statistical software
package available on Bioconductor [17-20].
Supervised analysis
The R package 'Linear Models for Microarray Data'
(LIMMA) was used for the assessment of differential
expression between N0 and N+ HNSCC subgroups in the
reference dataset [21]. Multiple testing correction was per-
formed using False Discovery Rate (FDR) analysis [22].
The reference dataset was used as the hypothesis generat-
ing dataset, and genes with a FDR adjusted p-value < 0.1
were included in the gene set that was subsequently vali-
dated using the independent validation dataset. Genes
were considered to be validated by the validation dataset
if an FDR adjusted p-value < 0.05 was reached.
In the study by Roepman et al. it was reported that longer
sample storage time had an adverse effect on the predic-
tive value of classifying genes, and that the classifying gene
set based on samples stored after 1998 had a higher accu-
racy [3]. In order to evaluate whether storage time had an
effect on the gene-based analysis in this study, we per-
formed an additional LIMMA analysis on samples stored
after 1998 in the reference dataset and subsequently vali-
dated the outcome using samples stored after 1998 in the
validation dataset.
Table 1: Characteristics of tumors included in the reference and 
validation dataset
Characteristic Reference set Validation set
Sex (n – %)
Male 60 (58%) 14 (64%)
Female 44 (42%) 8 (36%)
Location of primary tumor (n – %)
oral cavity 87 (84%) 7 (32%)
oropharynx 17 (16%) 7 (32%)
larynx 0 (0%) 8 (36%)
Primary tumor size (n – %)
Maximal diameter (cm.)
< 2.5 33 (32%) 0 (0%)
2.5 – 5.0 49 (47%) 13 (59%)
> 5.0 22 (21%) 9 (41%)
Nodal metastasis (n – %)
no (N0) 49 (47%) 11 (50%)
yes (N+) 55 (53%) 11 (50%)BMC Cancer 2008, 8:168 http://www.biomedcentral.com/1471-2407/8/168
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Pathway selection and analysis
In order to acquire metastatic potential, a primary tumor
cell must complete a series of sequential steps, including
progressive growth at the primary tumor site, vascularisa-
tion of the primary tumor, invasion of the surrounding
stroma, detachment from other tumor cells, embolization
of tumor cells in blood vessels or lymph vessels, survival
within these vessels, extravasation and proliferation at the
metastatic site [23]. Each of these steps is regulated by
transient or permanent changes in DNA, RNA or proteins.
We have defined pathways and gene sets involved in each
of these steps using the publicly available pathway data-
bases KEGG and Biocarta, and by researching literature on
metastasis in (head and neck) carcinoma [11-13]. We cat-
egorized these pathways in the following subgroups: sur-
vival, proliferation, differentiation, apoptosis, cell
adhesion, extra cellular matrix signaling and remodeling,
hypoxia and angiogenesis. In all, 241 gene sets were thus
created. In order to determine if gene expression was sig-
nificantly different between metastasized and non-metas-
tasized HNSCC in the reference dataset, we performed the
global test designed by J.J. Goeman (available as the R
package 'globaltest' at Bioconductor) on each predefined
pathway [19,20,24]. The reference dataset was used as the
hypothesis generating dataset, and all pathways with a
FDR adjusted p-value < 0.1 were accepted for validation in
the independent validation dataset. Pathways were con-
sidered to be validated by the validation dataset if an FDR
adjusted p-value < 0.05 was reached.
Results
Unsupervised analysis of the validation dataset
2 out of 24 hybridizations were of insufficient quality,
leaving 22 samples in the analysis (11 metastasized and
11 non-metastasized samples) (Table 1). No differences
were observed in total RNA and cRNA yield or quality
between samples with different storage time. After nor-
malization of the validation dataset, there was a great sim-
ilarity in gene-expression profiles irrespective of their N-
stage or location in the oral cavity, oropharynx, or larynx.
Complete linkage two-way hierarchical clustering
revealed no well-defined grouping of samples according
to their N-stage or location. No grouping was found
according to sample storage time. We also performed this
clustering analysis separately for each subgroup (accord-
ing to localization or N-stage), but found no stable clus-
ters (data not shown).
Supervised gene-based analysis
LIMMA analysis revealed 31 significant differentially
expressed oligonucleotide transcripts within the reference
dataset, when corrected for multiple testing (FDR adjusted
p-value < 0.1). Twenty-six of these 31 transcripts repre-
sented well-defined genes. Twenty-one of these 26 well-
defined genes were also represented on the HG U95 Av2
chip used in creating the validation dataset. Seven of these
21 genes appeared to be significantly expressed in the val-
idation dataset (raw p value < 0.05). However, all failed to
pass the correction for multiple testing (FDR adjusted p-
value < 0.05). These genes are lethal giant larvae protein 2
of Drosophila (LLGL2), fibroblast activation protein
alpha (FAP), urokinase plasminogen activator (PLAU),
laminin beta 1 (LAMB1), musculin (MSC), and collagen
type V alpha 1 and 3 subunits (COL5A1 and COL5A3)
(Table 2). Next, in analogy with the study by Roepman et
al., we performed LIMMA analysis on the samples stored
after 1998 only (66 samples in the reference dataset and 8
in the validation dataset) [3]. This revealed 352 differen-
tially expressed well-defined genes in the reference dataset
when corrected for multiple testing. However, none of
these genes could be validated (FDR adjusted p-value <
0.05) in the validation dataset (data not shown).
Supervised pathway-based analysis
Analysis of the selected pathways related to survival, pro-
liferation, apoptosis, cell adhesion, extra cellular matrix
signaling and remodeling, hypoxia and angiogenesis,
revealed significant differential expression for 23 gene sets
in the reference dataset. These gene sets mainly encode
extracellular matrix components (i.e. collagens), and
pathways involved in extracellular matrix remodeling
(MMPs, the uPA system, uPA regulating pathways, and
HIF1α regulated invasion), hypoxia (upregulation of
HIF1α target genes) and hypoxia induced angiogenesis
(HIF1α regulated angiogenic factors). Of these 23 gene
sets, 7 gene sets were validated by analysis of the inde-
pendent expression dataset when corrected for multiple
testing (Table 3 and 4). These gene sets with significant
differential expression between N0 and N+ tumors in
both datasets are involved in extracellular matrix remode-
ling (MMPs, MMP regulating pathways and the uPA sys-
tem), hypoxia and angiogenesis (HIF1α regulated
angiogenic factors and HIF1α regulated invasion) (Table
4 and 5, Figure 1). No significant differential expression
between metastasized and non-metastasized HNSCC was
shown for 215 gene sets in both datasets, including
almost all survival, proliferation and apoptosis related
gene sets (Table 3).
Discussion
It has been demonstrated that the outcome of microarray
studies is profoundly influenced by the chosen analysis
strategy and highly dependent on technical aspects such
as sample preparation methods and choice of microarray
platform [4-10]. This raises questions about the biological
validity of the outcome of individual studies, and the val-
idation of microarray studies is therefore essential. Here
we present the results of an independent validation anal-
ysis of differences in gene expression between metasta-
sized and non-metastasized HNSCC. The reference studyBMC Cancer 2008, 8:168 http://www.biomedcentral.com/1471-2407/8/168
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and validation study were performed in different centers
by different investigators, using different microarray plat-
forms with different probe content. In this study, we con-
centrated on the validation and biological interpretation
of the differences in gene expression between N0 and N+
HNSCC subgroups, and did not attempt to validate classi-
fying gene sets that predict N-status in the reference study
or other HNSCC microarray studies, because the data-
driven way in which these classifying gene sets are created
makes them too dependent on the microarray platform,
the microarray technique, the preprocessing methods and
the laboratory used to create them [4-8]. Furthermore,
gaining insight into the process of metastasis on the basis
of these classifying gene sets is troublesome: although
some probes within the classifier encode a gene with a
known role in tumorigenesis or metastasis, many others
have unrelated or unknown functions [3]. The fact that
multiple classifying gene sets can be constructed on basis
of the reference study data casts further doubts on their
biological validity [10]. In this study, a gene-based analy-
Table 2: Differentially expressed genes between N0 and N+ HNSCC as validated by the independent expression dataset
Gene GenBank ID Function P-Value P-Value (FDR adjusted)
LLGL2 NM_001031803 cell division and migration 0.011 0.116
FAP NM_004460 ecm remodelling 0.013 0.116
PLAU NM_002658 ecm remodelling 0.017 0.116
LAMB1 NM_002291 basement membrane component 0.022 0.116
MSC NM_005098 transcription factor 0.030 0.126
COL5A1 NM_000093 ecm component 0.039 0.134
COL5A3 NM_015719 ecm component 0.045 0.134
COL4A1 NM_001845 ecm component 0.077 0.201
LAMA4 NM_002290 basement membrane component 0.103 0.240
CYB5R3 NM_000398 Metabolism 0.237 0.488
CSTA NM_005213 cell envelope 0.255 0.488
PPL NM_002705 cell envelope 0.283 0.496
NTHL1 NM_002528 DNA damage repair 0.454 0.682
TNFAIP3 NM_006290 inhibit TNF-mediated apoptosis. 0.477 0.682
TTYH1 NM_020659 chloride anion channel 0.487 0.682
PALM2-AKAP2 NM_147150 Unknown 0.617 0.809
SCRG1 NM_007281 response to prion-associated infection 0.727 0.866
ADAM12 NM_021641 ecm remodelling 0.742 0.866
FADS1 NM_013402 Metabolism 0.869 0.888
SOX4 NM_003107 apoptosis and survival 0.876 0.888
IVL NM_005547 cell envelope 0.888 0.888
FN1 NM_212482 cell adhesion and migration - -
PELO NM_181501 cell cycle control - -
FBXL19 NM_019085 F-box protein - -
DMKN NM_033317 Unknown - -
EPPK1 NM_031308 cell adhesion - -
ecm = extra cellular matrix. P-value = raw p-value of the LIMMA analysis. P-value (FDR adjusted) = p-value of the LIMMA analysis, corrected for 
multiple testing. P-values for genes that were not represented on the Affymetrix HG U95Av2 microarray used for the validation dataset are 
missing. Differentially expressed genes are considered to be validated by the validation dataset if the FDR adjusted p-value is smaller than 0.05. 
Although the first 7 genes (LLGL2, FAP, PLAU, LAMB1, MSC, COL5A1 and COL5A3) score a raw p-value smaller than 0.05, none of them pass the 
correction for multiple testing.
Table 3: Number of pathways with significant differential expression between N0 and N+ HNSCC in the reference and validation 
datasets
Pathways significant in validation dataset Pathways not significant in validation 
dataset
Pathways significant in reference dataset 71 6
Pathways not significant in reference 
dataset
32 1 5
In all, 241 different tumorigenesis and metastasis related pathways were tested. 23 significant differentially expressed pathways were found in the 
reference dataset, and 10 in the validation dataset, 7 of which overlapped. 215 pathways showed no significant differential gene expression in both 
datasets.BMC Cancer 2008, 8:168 http://www.biomedcentral.com/1471-2407/8/168
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Heatmap of pathways with validated differential gene expression between non-metastasized and metastasized primary HNSCC Figure 1
Heatmap of pathways with validated differential gene expression between non-metastasized and metastasized 
primary HNSCC. Each row in the figure denotes a gene and each column denotes a sample. Panel on the left: validated dif-
ferentially expressed pathways in the reference study. Panel on the right: validated differentially expressed pathways in the val-
idation study. Relative gene-expression is shown for each gene in the pathway, and for each sample in the N0 and N1 HNSCC 
subgroups, red indicating overexpression and green indicating underexpression. White brackets indicate genes not repre-
sented on the respective microarray platforms.BMC Cancer 2008, 8:168 http://www.biomedcentral.com/1471-2407/8/168
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Table 4: Validated pathways with significant differential expression between N0 and N+ HNSCC
Pathways Genes in pathway Probes in reference 
dataset (n)
Probes in validation 
dataset (n)
p-value p-value (FDR adjusted)
MAPK 1/3 regulated 
MMPs
16 17 14 0.003 0.028
JNK/MAPK regulated 
MMPs
25 28 19 0.003 0.028
MAPK 1/3 regulated 
invasion
35 38 30 0.004 0.028
MMPs 9 8 8 0.005 0.028
HIF1α regulated invasion 14 11 11 0.011 0.048
HIF1α regulated 
angiogenesis
26 21 19 0.013 0.048
uPA system 3 3 2 0.015 0.048
Genes in pathway = number of genes theoretically involved in the pathway. Probes in reference dataset = number of probes representing pathway 
genes in the reference dataset. Probes in validation dataset = number of probes representing pathway genes in the validation dataset. P-value = raw 
p-value of the global test. P-value (FDR adjusted) = p-value of the global test, corrected for multiple testing using the false discovery rate. 
Differentially expressed pathways are considered to be validated by the validation dataset if the FDR adjusted p-value is smaller than 0.05.
Table 5: Genes included in the pathways and functional gene sets that are differentially expressed between metastasized and non-
metastasized HNSCC
uPA system HIF1A regulated 
angiogenesis
HIF1A regulated 
invasion
MMPs in 
HNSCC
MAPK 1/3 
regulated 
invasion
JNK/MAPK 
regulated MMPs
MAPK 1/3 
regulated MMPs
PLAU HGF HIF1A MMP1 SHC1 HRAS SHC1
PLAUR FGF2 MMP2 MMP2 GRB2 RAC1 GRB2
PLG PDGFB MMP13 MMP3 SOS1 PAK1 SOS1
IL8 PLAUR MMP6 HRAS PAK2 HRAS
PGF P4HA1 MMP7 RAF1 MAP3K4 RAF1
ANGPT2 CXCL12 MMP9 MAP2K1 MAP3K1 MAP2K1
TEK MMP14 MMP10 MAP2K2 MAP3K12 MAP2K2
MMP2 COL5A1 MMP11 MAPK3 MAP2K7 MAPK3
MMP13 CTGF MMP14 MAPK1 MAP2K4 MAPK1
PLAUR ITGB2 RPS6KA5 MAPK8 FOS
CCL2 SERPINE 1 RPS6KA1 MAPK9 MMP1
CXCL12 CXCR 4 MKNK1 MAPK10 MMP3
VEGFA MET MKNK2 JUN MMP7
FLT 1 ETS 1 MYC ATF2 MMP9
IGFBP1 ELK1 SP1 MMP10
SERPINE 1 STAT3 ELK1 MMP13
P4HA1 TERT JUND
CXCR 4 SRF CDC42
COL5A1 ELK4 CD44
CTGF ATF4 MMP1
MMP14 FOS MMP3
HIF1A RASA2 MMP7
ENG NF1 MMP9
EDN 1 RASA1 MMP10
LRP 1 RASGRF1 MMP13
CITED 2 RASGRP1
RAPGEF2
PRKCA
CD44
MMP1
MMP3
MMP7
MMP9
MMP10
MMP13BMC Cancer 2008, 8:168 http://www.biomedcentral.com/1471-2407/8/168
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sis revealed 7 genes that appeared to be significantly
expressed in the validation dataset (raw p value < 0.05)
(Table 2). All of these 7 genes are known to be involved in
processes of tumorigenesis or metastasis. LLGL2 belongs
to a group of genes that act as tumor suppressor genes.
Loss of function is associated with disruption of cell polar-
ity and tissue architecture, uncontrolled proliferation and
growth of neoplastic lesions [25]. FAP is a cell-surface pro-
tease expressed in reactive stromal fibroblasts of epithelial
cancers, and is associated with invasion and metastasis in
gastric, colorectal and cervical carcinoma [26-28]. PLAU
encodes a serine protease involved in degradation of the
extracellular matrix. Its plays a well-known role in inva-
sion and metastasis of carcinoma, and is a prognostic fac-
tor for metastasis and outcome [29,30]. LAMB1 encodes
the  β1 subunit of members from the laminin family,
extracellular matrix glycoproteins that are the major non-
collagenous constituent of basement membranes. Lam-
inins containing the β1 subunit (i.e. laminin 8 and 10)
have been implicated in the metastasis related processes
of angiogenesis, invasion, and migration [31,32]. The pro-
tein encoded by MSC is a transcriptional repressor that
attenuates E2A-mediated gene activation. MSC overex-
pression is associated with loss of differentiation in mul-
tiple tissues and is associated with B-cell lymphoma, but
no association with epithelial cancer has been described
to date [33,34]. COL5A1 and COL5A3 encode alpha
chains of collagen type 5. Upregulation is associated with
metastatic potential in carcinoma [3,35]. However, when
corrected for multiple testing, none of these genes could
be statistically validated.
Roepman et al. have reported an adverse effect of long-
term storage of tissue samples on its predictive accuracy.
No explanation was found for this phenomenon, but it
did not seem to be attributable to differences in total RNA
and cRNA yield or quality [3]. We have evaluated the
effect of storage time on the gene-based validation analy-
sis in this study. Our LIMMA analysis of the most recent
tumor samples within the reference dataset identified
more differentially expressed genes, an observation that
seems to correlate well with the findings of Roepman et al.
[3]. However, we do not find an effect of sample storage
time on the outcome of our validation analysis as none of
these genes are statistically validated by the most recent
samples in the validation dataset.
The gene-based validation between the reference and val-
idation studies was hampered by the use of different
microarray platforms with different probes and probe
content. In order to overcome this problem, a pathway-
based supervised analysis was performed, evaluating dif-
ferences in gene expression between metastasized and
non-metastasized HNSCC for predefined tumorigenesis-
and metastasis related pathways and gene sets. By analyz-
ing groups of functionally related genes, we were able to
study the same biological processes in both reference and
validation datasets, even though not all genes involved in
these processes were present, and the number and nature
of the represented genes varied in the respective datasets.
In this way, 7 metastasis-related pathways and function-
ally related gene sets that differentiate between metasta-
sized and non-metastasized HNSCC were statistically
validated (Table 4 and Figure 1). These validated path-
ways are metalloproteinases and regulatory pathways of
metalloproteinases, HIF1α induced invasion- and angio-
genesis related target genes and the urokinase plasmino-
gen activator system, key pathways involved in invasion,
extra cellular matrix remodelling, detachment and angio-
genesis, essential steps in the progression to metastatic
disease (Tables 4 and 5). Metalloproteinases play a com-
plex role in tumor progression and metastasis. Not only
do they facilitate invasion by degrading components of
the extracellular matrix, there is also evidence that they are
involved in angiogenesis. MMPs that induce metastasis
are not only produced by the tumor cells but also by stro-
mal cells and leucocytes, especially along the invasive
front of the tumor [36]. The second messenger signalling
pathways that lead to expression of MMPs are not fully
understood, but there is evidence that MAPK pathways are
involved [37]. Three different regulatory MAPK pathways
of MMPs have been identified, and in this study two of
them show significant differential expression between
metastasized and non-metastasized HNSCC: the MAPK1/
3 (ERK1/2) and JNK/MAPK pathways. The MAPK1/3
pathway, which is activated by a variety of mitogenic and
growth factors, induces FOS and JUN phosphorylation
and expression. The JNK/MAPK pathway, which is
induced by various inflammatory cytokines, increases
transcriptional activity and protein stability of JUN. FOS
and JUN are leucine zipper proteins that can dimerize
forming the AP-1 transcription factor complexes. JUN,
FOS and AP-1 complexes seem to regulate expression of
multiple MMPs [37]. The urokinase plasminogen activa-
tor system (uPA) mediates invasion and metastasis by cat-
alysing extracellular matrix dissolution, and there is
evidence that the uPA system plays a role in cell prolifera-
tion, migration and modulation of cell adhesion as well.
The potential of components of this system as prognosti-
cators in cancer has been evaluated most extensively in
breast cancer, but also in HNSCC [38]. PLAU in particular
seems to correlate well with unfavourable outcome, and
in this study PLAU correlated well with metastatic HNSCC
in both the reference and validation datasets. Hypoxia is a
common feature in solid tumors and their metastasis, and
can lead to tumor progression in a variety of ways. It
induces HIF1α, a transcription factor that regulates angio-
genesis as well as cell survival, invasion and metastasis by
activating transcription of a host of target genes. The gene
sets comprised of HIF1α target genes that are known to beBMC Cancer 2008, 8:168 http://www.biomedcentral.com/1471-2407/8/168
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involved in angiogenesis and invasion are significantly
upregulated in metastasized HNSCC in this study [39-41].
As oligonucleotide microarrays measure mRNA levels,
results reflect the gene-expression levels in N0 and N+
HNSCC. Post-transcriptional events such as splicing,
translation or activation of the proteins encoded by these
genes are not measured. Upregulation of genes in a spe-
cific pathway as determined by oligonucleotide microar-
rays therefore may not necessarily mean heightened
activity of the pathway. However, it is very plausible that
the observed differences in gene-expression levels of genes
involved in metastasis-related pathways are responsible
for the differences in metastatic potential of N0 and N+
HNSCC.
The aim of this study is not only to identify and validate a
gene-expression profile that characterizes metastatic dis-
ease in head and neck squamous cell carcinoma, but to
provide an analysis strategy that incorporates the available
insights in the pathways that lead to metastasis. This
supervised pathway-based analysis will not reveal new,
previously unknown metastasis related biomarkers. It
does however increase our understanding of the biologi-
cal context of the results. By focusing on pathways and
functional gene sets, rather than individual genes, the
insight into the biological steps that lead from carcinogen-
esis to metastatic disease in HNSCC is enhanced. Further-
more, by leaving probes that are not relevant to the
biological processes of interest out of the analysis, statisti-
cal noise and multiple testing problems associated with
microarray analysis are reduced. The most important
advantage of this strategy however is the increased compa-
rability of data from different microarray studies. Microar-
ray analyses based on individual genes are highly
dependent on the exact gene content of the microarray
used in the study, and thus on the chosen microarray plat-
form. In a pathway-based analysis however, gene expres-
sion does not have to be measured from every single gene
involved in a specific pathway, as long as a representative
subset of genes is assessed. These representative subsets of
genes involved in a specific pathway may vary between
studies. A pathway-based analysis thus can reveal biologi-
cally relevant similarity between results of different micro-
array studies even though the gene contents of the
microarray platforms used do not match exactly.
Conclusion
In this gene-expression study, we were able to identify and
validate several pathways that are differentially expressed
between metastasized and non-metastasized HNSCC.
These pathways are involved in the processes of extracel-
lular matrix remodeling (MMPs, MMP  regulating path-
ways and the uPA  system), hypoxia and angiogenesis
(HIF1α regulated angiogenic factors and HIF1α regulated
invasion). By focusing on pathways and functional gene
sets instead of individual probes in the analysis of micro-
array data, the biological context of the results is readily
interpretable. Furthermore, a supervised, pathway-based
analysis reduces multiple testing problems associated
with microarray analysis by focusing on a limited number
of pathways instead of analyzing all of the probes availa-
ble on the microarray. Most importantly, the comparabil-
ity of results from different microarray studies is greatly
improved. A supervised, pathway based analysis can
reveal biologically relevant similarity between results of
different gene-expression studies, even if studies have
used different microarray platforms with different probes
and probe content.
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